A Northwestern Medicine study published in Nature Medicine, used a new technique called spatial transcriptomics to examine the brain's response to Alzheimer's therapies, revealing new molecular targets that could enhance the effectiveness of current therapies and not just slow the disease, but potentially improve patient outcomes.

David Gate, PhD, assistant professor of Neurology in the Ken and Ruth Davee Department of Neurology and director of the Abrams Research Center on Neurogenomics, led this research.